I have been a member of NMC (Näringslivets Miljöchefer, or in English "the Swedish Association of Environmental Managers") for several years. Participation in NMC's meetings is a good opportunity to learn more within the field of sustainability, CSR (Corporate Social Responsibility) and environmental matters. It also presents a brilliant way to build your network.
Today I participated in an NMC full-day training course on CSR. Roughly 20 environmental managers from several different companies and organizations gathered together at the ÅF (Ångpanneföreningen) office at Frösundaleden 2. Mattis Bergquist from OnlyR guided them through the day.
Mattis had invited me to discuss for an hour with him and the course participants on CSR in general, on green pharmaceuticals and green economic incentives specifically, and on this blog as a novel, interesting interactive communication tool.
I used my blog post from yesterday to described different parts of a CSR-platform for the pharmaceutical industry. We had a good discussion on possible reasons why the pharmaceutical industry has not been very successful in telling their CSR story to its stakeholders. One reason of course being the fact that we are not allowed to talk about our products (i.e. the prescription medicines) with the general public. Nevertheless the industry seems to have stronger product brand names than corporate brand names. Personally you may know if you follow this blog, that I feel that the industry have been a poor communicator. We have been very slow in adopting modern communication tools, e.g. social media, and to me it is very surprising that there are still recommendations to stay away from social media... Does not feel like 2011, does it? For more on the issue please read my blog post from Nov 24 last year.
We also had a good discussion on potential negative environmental consequences of the Swedish generic reform, where the pharmacy is forced to substitute the prescribed pharmaceutical with the "product of the month" (in Swedish "periodens vara"), i.e. the cheapest generic. And this regardless of any environmental profiles. This of course took us to the discussion on green pharmaceuticals and green economic incentives, that you know I am very engaged in. To read more on the topic, read my blog post from Oct 3, 2011, and follow the links within that blog post for details.
Thanks NMC, Mattis, and all very engaged course participants for very good and intense discussions. I enjoyed it very much!